RxDoctor Payments Data

Geneva Curry

Family · Greenville, MSNPI 1740359892

Payments from drug & device makers

$522in general payments, 2019–2025

Across 17 payments — averaging $30.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$146
  • AstraZeneca$124
  • Global Blood Therapeutics, Inc.$81
  • Mylan Specialty L.p.$70
  • Alpha Cognition USA, Inc.$32
  • Hikma Pharmaceuticals USA$25
  • plus $45 from 3 others

What the payments were for

  • Speaking & faculty fees$153%
  • Food & beverage$50797%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim2$146
AstraZeneca1$124
Global Blood Therapeutics, Inc.4$81
Mylan Specialty L.p.4$70
Alpha Cognition USA, Inc.1$32
Hikma Pharmaceuticals USA2$25
Otsuka America Pharmaceutical, Inc.1$18
Mckesson Medical-surgical, Inc.1$15
Lilly USA, LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$522 in reported general payments places this provider in the 55th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$26,979
Medicare patients
109
Services billed
766

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide36$49,181
JanuviaSitagliptin Phosphate39$45,780
EliquisApixaban70$40,199
FarxigaDapagliflozin Propanediol31$30,694
JardianceEmpagliflozin26$26,196
TradjentaLinagliptin16$23,139
XareltoRivaroxaban26$20,080
LinzessLinaclotide25$19,259
Tresiba Flextouch U-100Insulin Degludec16$15,112
JanumetSitagliptin Phos/Metformin Hcl13$12,140
EntrestoSacubitril/Valsartan24$11,947
TrulicityDulaglutide12$11,797
MitigareColchicine32$9,693
SymbicortBudesonide/Formoterol Fumarate38$9,652
Trijardy XrEmpaglifloz/Linaglip/Metformin13$7,186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr$146$56,52155 claims
AstraZenecaFarxiga, Symbicort$124$40,34669 claims
Lilly USA, LLCTrulicity$12$11,79712 claims
Hikma Pharmaceuticals USAMitigare$25$9,69332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,007 family providers in Mississippi.

Other family in Greenville

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →